|Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2–positive breast cancer|
J Shou, S Massarweh, CK Osborne, AE Wakeling, S Ali, H Weiss, R Schiff
Journal of the National Cancer Institute 96 (12), 926-935, 2004
|Mechanisms of endocrine resistance in breast cancer|
CK Osborne, R Schiff
Annual review of medicine 62, 233-247, 2011
|Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer|
CK Osborne, V Bardou, TA Hopp, GC Chamness, SG Hilsenbeck, ...
Journal of the National Cancer Institute 95 (5), 353-361, 2003
|Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes|
RM Lavinsky, K Jepsen, T Heinzel, J Torchia, TM Mullen, R Schiff, ...
Proceedings of the National Academy of Sciences 95 (6), 2920-2925, 1998
|Estrogen receptor–positive, progesterone receptor–negative breast cancer: association with growth factor receptor expression and tamoxifen resistance|
G Arpino, H Weiss, AV Lee, R Schiff, S De Placido, CK Osborne, ...
Journal of the National Cancer Institute 97 (17), 1254-1261, 2005
|Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance|
G Arpino, L Wiechmann, CK Osborne, R Schiff
Endocrine reviews 29 (2), 217-233, 2008
|Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase|
MC Gutierrez, S Detre, S Johnston, SK Mohsin, J Shou, DC Allred, ...
Journal of clinical oncology 23 (11), 2469-2476, 2005
|Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy|
X Cui, R Schiff, G Arpino, CK Osborne, AV Lee
Journal of clinical oncology 23 (30), 7721-7735, 2005
|Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer|
CK Osborne, J Shou, S Massarweh, R Schiff
Clinical cancer research 11 (2), 865s-870s, 2005
|Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function|
S Massarweh, CK Osborne, CJ Creighton, L Qin, A Tsimelzon, S Huang, ...
Cancer research 68 (3), 826-833, 2008
|The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo|
KL Meerbrey, G Hu, JD Kessler, K Roarty, MZ Li, JE Fang, JI Herschkowitz, ...
Proceedings of the National Academy of Sciences 108 (9), 3665-3670, 2011
|Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance|
R Schiff, SA Massarweh, J Shou, L Bharwani, SK Mohsin, CK Osborne
Clinical Cancer Research 10 (1), 331s-336s, 2004
|HER2: biology, detection, and clinical implications|
C Gutierrez, R Schiff
Archives of pathology & laboratory medicine 135 (1), 55-62, 2011
|Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response|
R Schiff, S Massarweh, J Shou, CK Osborne
Clinical Cancer Research 9 (1), 447s-454s, 2003
|Estrogen-receptor biology: continuing progress and therapeutic implications|
CK Osborne, R Schiff
Journal of Clinical Oncology 23 (8), 1616-1622, 2005
|A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models|
X Zhang, S Claerhout, A Prat, LE Dobrolecki, I Petrovic, Q Lai, MD Landis, ...
Cancer research 73 (15), 4885-4897, 2013
|A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis|
JD Kessler, KT Kahle, T Sun, KL Meerbrey, MR Schlabach, EM Schmitt, ...
Science 335 (6066), 348-353, 2012
|ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer|
R Jeselsohn, G Buchwalter, C De Angelis, M Brown, R Schiff
Nature reviews Clinical oncology 12 (10), 573, 2015
|Au nanomatryoshkas as efficient near-infrared photothermal transducers for cancer treatment: benchmarking against nanoshells|
C Ayala-Orozco, C Urban, MW Knight, AS Urban, O Neumann, ...
ACS nano 8 (6), 6372-6381, 2014
|MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis|
A Terunuma, N Putluri, P Mishra, EA Mathé, TH Dorsey, M Yi, TA Wallace, ...
The Journal of clinical investigation 124 (1), 398-412, 2014